Onkologie. 2013:7(3):127-129

Primary central nervous system lymphoma

Heidi Móciková
Interní hematologická klinika, FN Královské Vinohrady, Praha

Primary central nervous system lymphomas constitute a rare group of extranodal non-Hodgkin´s lymphoma with aggressive clinical

course and unsatisfactory outcome. High dose methotrexate based chemotherapy combined with whole brain radiotherapy is the current

standard of treatment. Combination of chemotherapy and whole brain radiotherapy improves response rate, however, the addition of

radiotherapy increases the risk of neurotoxicity. Radiotherapy alone is a therapeutic approach in older patients not suitable for systemic

chemotherapy. The significance of high dose chemotherapy with autologous stem cell transplantation and new drugs are investigated

in the current clinical trials in primary central nervous system lymphomas.

Keywords: primary central nervous system lymphoma, chemotherapy, methotrexate, radiotherapy

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Móciková H. Primary central nervous system lymphoma. Onkologie. 2013;7(3):127-129.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227-234. Go to original source... Go to PubMed...
    2. Bromberg JE, Siemers MD, Taphoorn MJ. Is a " vanishing tumor" always a lymphoma? Neurology 2002; 59: 762-764. Go to original source... Go to PubMed...
    3. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043. Go to original source... Go to PubMed...
    4. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272. Go to original source... Go to PubMed...
    5. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711-5715. Go to original source... Go to PubMed...
    6. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-4648. Go to original source... Go to PubMed...
    7. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735. Go to original source... Go to PubMed...
    8. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 2009; 374: 1512-1520. Go to original source... Go to PubMed...
    9. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-1047. Go to original source... Go to PubMed...
    10. Motomura K, Natsume A, Fujii M, et al. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma 2011; 52: 2069-2075. Go to original source... Go to PubMed...
    11. Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: Cerebral radiotherapy with or without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000; 89: 1369-1370. Go to original source...
    12. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALG50202 (Alliance 50202). J Clin Oncol 2013. Published ahead of print on April 8, 2013. DOI: 10.1200/JCO.2012.46.9957. Go to original source... Go to PubMed...
    13. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma. Societe Francaise de greffe de moelle osseuse-therapie cellulaire. J Clin Oncol 2008; 26: 2512-2518. Go to original source... Go to PubMed...
    14. Dědečková K, Mociková H, Belada D, et al. Postavení radioterapie v léčbě maligních lymfomů - doporučení Kooperativní lymfomové skupiny. Klinická onkologie 2013; 26: 99-109. Go to original source... Go to PubMed...
    15. Laack NN, Ballman KV, Brown PB, et al. North Central Cancer Treatment Group. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: results of North Central Cancer Treatment Group (NCCTG). Int J Radiat Oncol Biol Phys 2006; 65: 1429-1439. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.